Portage Biotech Inc. (PRTG)
USD 5.21
(-5.79%)
USD 5.21
(-5.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -75.33 Million USD | 27.98% |
| 2023 | -104.61 Million USD | -445.73% |
| 2022 | -19.16 Million USD | -11.52% |
| 2021 | -17.18 Million USD | -137.12% |
| 2020 | -7.24 Million USD | -175.1% |
| 2019 | -2.63 Million USD | -102.13% |
| 2018 | 123.74 Million USD | 659.21% |
| 2017 | 16.29 Million USD | 385.63% |
| 2016 | -5.7 Million USD | -82.98% |
| 2015 | -3.11 Million USD | 50.54% |
| 2014 | -6.3 Million USD | -335.85% |
| 2013 | -1.44 Million USD | 41.58% |
| 2012 | -2.47 Million USD | 35.45% |
| 2011 | -3.83 Million USD | 0.43% |
| 2010 | -3.85 Million USD | -605.61% |
| 2009 | -545.98 Thousand USD | 1.72% |
| 2008 | -555.52 Thousand USD | -290.66% |
| 2007 | -142.2 Thousand USD | 96.54% |
| 2006 | -4.1 Million USD | 1.81% |
| 2005 | -4.18 Million USD | -302.73% |
| 2004 | -1.03 Million USD | -377.03% |
| 2003 | -217.58 Thousand USD | 73.97% |
| 2002 | -835.74 Thousand USD | 23.3% |
| 2001 | -1.08 Million USD | -13.82% |
| 2000 | -957.25 Thousand USD | -202.45% |
| 1999 | -316.5 Thousand USD | 20.2% |
| 1998 | -396.64 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -75.33 Million USD | 27.98% |
| 2024 Q1 | -5.91 Million USD | 93.73% |
| 2024 Q4 | -24.88 Million USD | 36.79% |
| 2024 Q3 | -39.37 Million USD | -663.34% |
| 2024 Q2 | -5.15 Million USD | 12.86% |
| 2023 Q2 | -1.08 Million USD | 33.23% |
| 2023 Q4 | -94.44 Million USD | -1159.14% |
| 2023 FY | -104.61 Million USD | -445.73% |
| 2023 Q1 | -1.62 Million USD | 81.67% |
| 2023 Q3 | -7.5 Million USD | -591.34% |
| 2022 Q2 | -2.97 Million USD | 2.97% |
| 2022 Q3 | -3.51 Million USD | -18.05% |
| 2022 Q4 | -8.86 Million USD | -152.36% |
| 2022 FY | -19.16 Million USD | -11.52% |
| 2022 Q1 | -3.06 Million USD | 73.33% |
| 2021 Q1 | -696 Thousand USD | 46.54% |
| 2021 Q4 | -11.49 Million USD | -871.11% |
| 2021 FY | -17.18 Million USD | -137.12% |
| 2021 Q3 | -1.18 Million USD | 51.77% |
| 2021 Q2 | -2.45 Million USD | -252.73% |
| 2020 FY | -7.24 Million USD | -175.1% |
| 2020 Q1 | -1.44 Million USD | 25.05% |
| 2020 Q4 | -1.3 Million USD | -246.28% |
| 2020 Q3 | -376 Thousand USD | 70.46% |
| 2020 Q2 | -1.27 Million USD | 11.72% |
| 2019 Q4 | -1.92 Million USD | -579.86% |
| 2019 FY | -2.63 Million USD | -102.13% |
| 2019 Q3 | -283 Thousand USD | -36.06% |
| 2019 Q1 | -219 Thousand USD | -100.18% |
| 2019 Q2 | -208 Thousand USD | 5.02% |
| 2018 Q3 | -351 Thousand USD | -2.93% |
| 2018 Q1 | -333.03 Thousand USD | 96.21% |
| 2018 FY | 123.74 Million USD | 659.21% |
| 2018 Q2 | -341 Thousand USD | -2.39% |
| 2018 Q4 | 124.76 Million USD | 35645.87% |
| 2017 Q2 | 33.86 Million USD | 1349.69% |
| 2017 FY | 16.29 Million USD | 385.63% |
| 2017 Q4 | -8.78 Million USD | -44.57% |
| 2017 Q3 | -6.07 Million USD | -117.94% |
| 2017 Q1 | -2.7 Million USD | -136.65% |
| 2016 Q1 | -790.9 Thousand USD | 18.2% |
| 2016 Q2 | -1.01 Million USD | -28.37% |
| 2016 Q4 | -1.14 Million USD | 58.44% |
| 2016 Q3 | -2.75 Million USD | -171.35% |
| 2016 FY | -5.7 Million USD | -82.98% |
| 2015 Q3 | -637.15 Thousand USD | 12.56% |
| 2015 Q1 | -785.63 Thousand USD | 52.84% |
| 2015 Q2 | -728.71 Thousand USD | 7.25% |
| 2015 FY | -3.11 Million USD | 50.54% |
| 2015 Q4 | -966.92 Thousand USD | -51.76% |
| 2014 Q2 | -348.31 Thousand USD | 91.29% |
| 2014 Q3 | -292.22 Thousand USD | 16.11% |
| 2014 Q1 | -3.99 Million USD | -732.25% |
| 2014 FY | -6.3 Million USD | -335.85% |
| 2014 Q4 | -1.66 Million USD | -470.11% |
| 2013 FY | -1.44 Million USD | 41.58% |
| 2013 Q4 | -480.44 Thousand USD | -252.28% |
| 2013 Q2 | -2.2 Million USD | -350.28% |
| 2013 Q1 | 881.54 Thousand USD | 259.57% |
| 2013 Q3 | 315.49 Thousand USD | 114.3% |
| 2012 FY | -2.47 Million USD | 35.45% |
| 2012 Q4 | -552.44 Thousand USD | -35.2% |
| 2012 Q3 | -408.61 Thousand USD | 37.02% |
| 2012 Q1 | -901.93 Thousand USD | 5.73% |
| 2012 Q2 | -648.8 Thousand USD | 28.07% |
| 2011 Q1 | -460.73 Thousand USD | 80.18% |
| 2011 Q3 | -1.06 Million USD | 17.36% |
| 2011 FY | -3.83 Million USD | 0.43% |
| 2011 Q4 | -956.73 Thousand USD | 10.14% |
| 2011 Q2 | -1.28 Million USD | -179.62% |
| 2010 FY | -3.85 Million USD | -605.61% |
| 2010 Q1 | -177.12 Thousand USD | 10.83% |
| 2010 Q2 | -713.89 Thousand USD | -303.04% |
| 2010 Q3 | -602.46 Thousand USD | 15.61% |
| 2010 Q4 | -2.32 Million USD | -285.9% |
| 2009 Q3 | -226.57 Thousand USD | -89.23% |
| 2009 Q2 | -119.73 Thousand USD | -502.65% |
| 2009 Q1 | -19.86 Thousand USD | -143.17% |
| 2009 Q4 | -198.63 Thousand USD | 12.33% |
| 2009 FY | -545.98 Thousand USD | 1.72% |
| 2008 Q2 | -255.25 Thousand USD | -57.94% |
| 2008 Q3 | -171.92 Thousand USD | 32.65% |
| 2008 Q1 | -161.61 Thousand USD | -161.39% |
| 2008 Q4 | 46.02 Thousand USD | 126.77% |
| 2008 FY | -555.52 Thousand USD | -290.66% |
| 2007 Q1 | -339.84 Thousand USD | -439.77% |
| 2007 Q3 | -2159.40 USD | 97.36% |
| 2007 Q2 | -81.88 Thousand USD | 75.9% |
| 2007 Q4 | 263.26 Thousand USD | 12291.38% |
| 2007 FY | -142.2 Thousand USD | 96.54% |
| 2006 Q1 | -1.13 Million USD | 67.23% |
| 2006 Q3 | -133.5 Thousand USD | 95.07% |
| 2006 FY | -4.1 Million USD | 1.81% |
| 2006 Q2 | -2.7 Million USD | -138.41% |
| 2006 Q4 | -62.95 Thousand USD | 52.84% |
| 2005 Q3 | -97.57 Thousand USD | 58.46% |
| 2005 FY | -4.18 Million USD | -302.73% |
| 2005 Q4 | -3.46 Million USD | -3451.65% |
| 2005 Q2 | -234.87 Thousand USD | 13.07% |
| 2005 Q1 | -270.18 Thousand USD | 68.56% |
| 2004 Q3 | -49.18 Thousand USD | 49.22% |
| 2004 FY | -1.03 Million USD | -377.03% |
| 2004 Q2 | -96.85 Thousand USD | -254.96% |
| 2004 Q4 | -859.4 Thousand USD | -1647.31% |
| 2004 Q1 | -27.28 Thousand USD | 21.57% |
| 2003 Q1 | -45.98 Thousand USD | 81.02% |
| 2003 Q4 | -34.79 Thousand USD | 59.02% |
| 2003 Q2 | -53.16 Thousand USD | -15.61% |
| 2003 FY | -217.58 Thousand USD | 73.97% |
| 2003 Q3 | -84.89 Thousand USD | -59.69% |
| 2002 Q2 | -53.6 Thousand USD | -10.04% |
| 2002 Q3 | -494.09 Thousand USD | -821.77% |
| 2002 FY | -835.74 Thousand USD | 23.3% |
| 2002 Q4 | -242.23 Thousand USD | 50.97% |
| 2002 Q1 | -48.71 Thousand USD | 87.34% |
| 2001 Q3 | -347.79 Thousand USD | 0.0% |
| 2001 FY | -1.08 Million USD | -13.82% |
| 2001 Q4 | -384.73 Thousand USD | -10.62% |
| 2000 FY | -957.25 Thousand USD | -202.45% |
| 1999 FY | -316.5 Thousand USD | 20.2% |
| 1998 FY | -396.64 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 48.538% |
| Alkermes plc | 355.75 Million USD | 121.177% |
| Agenus Inc. | -245.76 Million USD | 69.345% |
| Aptorum Group Limited | -2.82 Million USD | -2567.201% |
| Ardelyx, Inc. | -66.06 Million USD | -14.034% |
| Dyadic International, Inc. | -6.79 Million USD | -1008.667% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -7949.038% |
| Lantern Pharma Inc. | -15.96 Million USD | -372.004% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -295.919% |
| Novavax, Inc. | -545.06 Million USD | 86.178% |
| Janux Therapeutics, Inc. | -58.29 Million USD | -29.242% |
| Pyxis Oncology, Inc. | -73.79 Million USD | -2.099% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -306.226% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -654.446% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | -27.731% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 79.836% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -209.537% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -101.765% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 54.222% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | -2.716% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -271.293% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -21.017% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -131.919% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 43.137% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 82.887% |
| AlloVir, Inc. | -190.41 Million USD | 60.435% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 63.299% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -164.793% |
| Bicycle Therapeutics plc | -180.66 Million USD | 58.299% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 57.924% |
| ChromaDex Corporation | -4.93 Million USD | -1425.699% |
| Chimerix, Inc. | -82.09 Million USD | 8.229% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -68.909% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 26.189% |
| CRISPR Therapeutics AG | -153.61 Million USD | 50.954% |
| Precision BioSciences, Inc. | -61.31 Million USD | -22.864% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 53.185% |
| Fortress Biotech, Inc. | -60.63 Million USD | -24.246% |
| Fortress Biotech, Inc. | -60.63 Million USD | -24.246% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 7.65% |
| ImmuCell Corporation | -5.77 Million USD | -1204.662% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 33.305% |
| Immix Biopharma, Inc. | -15.42 Million USD | -388.388% |
| Incyte Corporation | 597.59 Million USD | 112.607% |
| Innoviva, Inc. | 179.72 Million USD | 141.92% |
| IO Biotech, Inc. | -86.08 Million USD | 12.481% |
| Jaguar Health, Inc. | -41.3 Million USD | -82.419% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 50.756% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 244.455% |
| ContextLogic Inc. | -317 Million USD | 76.234% |
| MiMedx Group, Inc. | 67.43 Million USD | 211.714% |
| MEI Pharma, Inc. | 17.77 Million USD | 523.777% |
| NextCure, Inc. | -62.72 Million USD | -20.114% |
| Onconetix, Inc. | -37.4 Million USD | -101.389% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -90.833% |
| Opthea Limited | -220.24 Million USD | 65.793% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -47.264% |
| Vaxcyte, Inc. | -402.26 Million USD | 81.271% |
| PDS Biotechnology Corporation | -42.94 Million USD | -75.443% |
| Precigen, Inc. | -95.9 Million USD | 21.443% |
| Pharming Group N.V. | -10.54 Million USD | -614.249% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 62.628% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -206.967% |
| PureTech Health plc | -65.69 Million USD | -14.676% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -200.263% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 64.5% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -209.537% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 70.78% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -176.595% |
| Acelyrin, Inc. | -381.64 Million USD | 80.259% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -600560.624% |
| Summit Therapeutics Inc. | -614.92 Million USD | 87.748% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -120.929% |
| Senti Biosciences, Inc. | -92.91 Million USD | 18.92% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 28.042% |
| Elevation Oncology, Inc. | -45.7 Million USD | -64.841% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -114.397% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -476.345% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -1026.986% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -156.587% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -786.237% |
| Wave Life Sciences Ltd. | -57.51 Million USD | -30.995% |
| Seer, Inc. | -86.27 Million USD | 12.678% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | -12.455% |
| Aadi Bioscience, Inc. | -65.76 Million USD | -14.558% |
| ESSA Pharma Inc. | -26.58 Million USD | -183.417% |
| GlycoMimetics, Inc. | -36.89 Million USD | -104.174% |
| GT Biopharma, Inc. | -7.59 Million USD | -891.694% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 68.786% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | -45.092% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 205.502% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | -38.435% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -53.377% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -657.347% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 86.848% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1999.749% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -47.556% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 69.324% |
| Aptose Biosciences Inc. | -51.2 Million USD | -47.126% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 23.356% |
| Soligenix, Inc. | -6.14 Million USD | -1126.874% |
| Century Therapeutics, Inc. | -136.67 Million USD | 44.876% |
| Kura Oncology, Inc. | -152.63 Million USD | 50.64% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 15.556% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -614.927% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 13423.253% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -13140.598% |
| Autolus Therapeutics plc | -208.38 Million USD | 63.846% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | -4.786% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | -6.419% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -247.697% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 66.553% |
| GRI Bio, Inc. | -13.03 Million USD | -477.886% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -1722.169% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 39.284% |
| IGM Biosciences, Inc. | -246.41 Million USD | 69.426% |
| INmune Bio, Inc. | -30 Million USD | -151.063% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 31.856% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -78.555% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -372.0% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -376.981% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | -26.228% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 25.53% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 72.716% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 68.331% |
| Verastem, Inc. | -87.36 Million USD | 13.767% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -39.033% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 53.303% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 35.419% |
| Histogen Inc. | -10.62 Million USD | -609.34% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -427.335% |
| Surrozen, Inc. | -43.04 Million USD | -75.036% |
| Organovo Holdings, Inc. | -14.67 Million USD | -413.523% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -1381.002% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -43.944% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -198.219% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -179.676% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -801.498% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 50.135% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -53.985% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -153.453% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -623.182% |
| Apollomics, Inc. | -172.6 Million USD | 56.351% |
| Amarin Corporation plc | -59.11 Million USD | -27.451% |
| Mesoblast Limited | -87.95 Million USD | 14.345% |
| Turnstone Biologics Corp. | -55.2 Million USD | -36.484% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 48.736% |
| Synaptogenix, Inc. | -6.03 Million USD | -1147.643% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -364.826% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 3.436% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1472.358% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -796.658% |
| Exelixis, Inc. | 207.76 Million USD | 136.262% |
| Better Therapeutics, Inc. | -39.76 Million USD | -89.484% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 47.662% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 85.748% |
| NLS Pharmaceutics AG | -12.17 Million USD | -518.952% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -866.543% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -145.013% |
| Gritstone bio, Inc. | -138.49 Million USD | 45.6% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -16.868% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1783.499% |
| Avid Bioservices, Inc. | -140.75 Million USD | 46.474% |
| Insmed Incorporated | -749.56 Million USD | 89.949% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -395.994% |
| MediWound Ltd. | -6.71 Million USD | -1021.784% |
| OmniAb, Inc. | -50.61 Million USD | -48.835% |
| Alector, Inc. | -130.39 Million USD | 42.221% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 33.753% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -45.31% |
| Zai Lab Limited | -334.62 Million USD | 77.485% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 76.746% |
| Aura Biosciences, Inc. | -76.4 Million USD | 1.399% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 67.891% |
| Immunic, Inc. | -93.61 Million USD | 19.52% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 44.56% |
| Veracyte, Inc. | -74.4 Million USD | -1.257% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -881.545% |
| FibroGen, Inc. | -284.23 Million USD | 73.494% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -187.203% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -975.981% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -300.044% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 118.161% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -234.023% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 252.907% |
| TG Therapeutics, Inc. | 12.67 Million USD | 694.531% |
| Galecto, Inc. | -38.34 Million USD | -96.456% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -299.337% |
| Fortrea Holdings Inc. | -3.4 Million USD | -2115.853% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 40.511% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -332.709% |
| XBiotech Inc. | -24.55 Million USD | -206.792% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -16.868% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | -20.196% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 23.456% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -251.608% |
| Theravance Biopharma, Inc. | -55.19 Million USD | -36.501% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 87.581% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | -10.379% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -132226.905% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 66.743% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -238.336% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 65.71% |
| NexImmune, Inc. | -32.34 Million USD | -132.928% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -1325.101% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -436.377% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.906% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -211.048% |
| Scopus BioPharma Inc. | -11.6 Million USD | -548.924% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 35.496% |
| Ainos, Inc. | -13.77 Million USD | -447.102% |
| Pluri Inc. | -20.88 Million USD | -260.681% |
| Prothena Corporation plc | -147.02 Million USD | 48.759% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 33.838% |
| Celularity Inc. | -196.29 Million USD | 61.62% |
| Rallybio Corporation | -74.56 Million USD | -1.039% |
| Cue Biopharma, Inc. | -50.73 Million USD | -48.501% |
| MeiraGTx Holdings plc | -84.02 Million USD | 10.34% |
| Omeros Corporation | -117.81 Million USD | 36.052% |
| Humacyte, Inc. | -110.77 Million USD | 31.99% |
| Immunocore Holdings plc | -55.28 Million USD | -36.269% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -318.922% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -228.547% |
| Blueprint Medicines Corporation | -506.98 Million USD | 85.14% |
| CalciMedica, Inc. | -34.35 Million USD | -119.283% |
| Cabaletta Bio, Inc. | -67.67 Million USD | -11.325% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 46.721% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 54.557% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 73.402% |
| Pulmatrix, Inc. | -14.12 Million USD | -433.525% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -114.062% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 8.832% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 84.343% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 28.16% |
| Cytokinetics, Incorporated | -526.24 Million USD | 85.684% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -108.898% |
| Nutriband Inc. | -5.48 Million USD | -1273.467% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -86.39% |
| Vor Biopharma Inc. | -117.86 Million USD | 36.079% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 101.732% |
| Evogene Ltd. | -23.87 Million USD | -215.503% |
| ProKidney Corp. | -35.46 Million USD | -112.414% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 37.093% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -860.296% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 88.287% |
| CorMedix Inc. | -46.33 Million USD | -62.581% |
| BioLineRx Ltd. | -60.61 Million USD | -24.293% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 25.952% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -83.458% |
| Atai Life Sciences N.V. | -40.22 Million USD | -87.299% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 6.585% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 0.241% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 74.216% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -170.265% |
| MediciNova, Inc. | -8.57 Million USD | -778.946% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 38.886% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -799.373% |
| GeoVax Labs, Inc. | -25.96 Million USD | -190.136% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 68.509% |
| Biomea Fusion, Inc. | -117.25 Million USD | 35.748% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 87.977% |
| Mereo BioPharma Group plc | -29.46 Million USD | -155.681% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 50.811% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 64.015% |
| Absci Corporation | -110.56 Million USD | 31.861% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -149.881% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 25.286% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 68.068% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 634.926% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 60.957% |
| Allakos Inc. | -185.7 Million USD | 59.43% |
| Imunon, Inc. | -19.51 Million USD | -286.057% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 22.598% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 170.981% |
| BioAtla, Inc. | -123.46 Million USD | 38.978% |
| NLS Pharmaceutics AG | -12.17 Million USD | -518.952% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -368.584% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 76.979% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -103.9% |
| XOMA Corporation | -40.83 Million USD | -84.514% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 26.044% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 36.43% |
| aTyr Pharma, Inc. | -50.38 Million USD | -49.515% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 14.074% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 50.356% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 68.31% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -114.525% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -831.038% |
| Akari Therapeutics, Plc | -10 Million USD | -652.788% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -111803.453% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 126.754% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1030.385% |
| UroGen Pharma Ltd. | -102.24 Million USD | 26.315% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 29.453% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -868.718% |
| Orgenesis Inc. | -55.36 Million USD | -36.087% |
| Entera Bio Ltd. | -8.88 Million USD | -747.553% |
| GH Research PLC | -35.58 Million USD | -111.704% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -261.512% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 2.648% |
| Xencor, Inc. | -126.08 Million USD | 40.248% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -1900.663% |
| Replimune Group, Inc. | -215.79 Million USD | 65.088% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -254.261% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 3102.75% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1030.385% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -799.373% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 22.054% |
| OncoCyte Corporation | -27.78 Million USD | -171.189% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -461.51% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -577.416% |
| Purple Biotech Ltd. | -19.88 Million USD | -278.969% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -973.358% |
| scPharmaceuticals Inc. | -54.81 Million USD | -37.455% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -330.358% |
| HilleVax, Inc. | -123.56 Million USD | 39.029% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -645.414% |
| Tharimmune, Inc. | -9.31 Million USD | -708.437% |
| Genprex, Inc. | -30.86 Million USD | -144.128% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 68.067% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -150.346% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -4127.778% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -1322.56% |
| OKYO Pharma Limited | -16.82 Thousand USD | -447667.847% |
| Savara Inc. | -54.69 Million USD | -37.736% |
| Curis, Inc. | -47.41 Million USD | -58.899% |
| Daré Bioscience, Inc. | -30.16 Million USD | -149.786% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -387.786% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -1252.828% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -152.688% |
| BeiGene, Ltd. | -881.7 Million USD | 91.455% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -253.804% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 82.735% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 4.58% |
| Erasca, Inc. | -125.04 Million USD | 39.749% |
| bluebird bio, Inc. | -211.91 Million USD | 64.448% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -1406.63% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 144.94% |
| DBV Technologies S.A. | -72.72 Million USD | -3.593% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -1406.63% |
| Moderna, Inc. | -4.71 Billion USD | 98.402% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -87.611% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -1223.13% |
| Molecular Templates, Inc. | -8.12 Million USD | -827.363% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | -24.758% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 32.37% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 44.338% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -57.222% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 46.73% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 60.845% |
| MacroGenics, Inc. | -9.05 Million USD | -731.74% |
| RenovoRx, Inc. | -10.23 Million USD | -636.308% |
| Adicet Bio, Inc. | -142.65 Million USD | 47.189% |
| Prime Medicine, Inc. | -198.13 Million USD | 61.976% |
| Aditxt, Inc. | -32.38 Million USD | -132.665% |
| Adagene Inc. | -18.94 Million USD | -297.643% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -930.386% |
| Quantum-Si incorporated | -95.96 Million USD | 21.489% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 36.705% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -416.808% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 156.933% |
| SciSparc Ltd. | -5.12 Million USD | -1370.89% |
| Vericel Corporation | -3.18 Million USD | -2267.662% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -62549.891% |
| Minerva Neurosciences, Inc. | -30 Million USD | -151.085% |
| Generation Bio Co. | -126.61 Million USD | 40.496% |
| Astria Therapeutics, Inc. | -72.89 Million USD | -3.358% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 8.616% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 71.26% |
| Invivyd, Inc. | -198.64 Million USD | 62.073% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 77.969% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -767.304% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 430.347% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -663.004% |
| 2seventy bio, Inc. | -217.57 Million USD | 65.373% |
| ADMA Biologics, Inc. | -28.23 Million USD | -166.791% |
| Clene Inc. | -49.5 Million USD | -52.188% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -238.032% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -52.403% |
| GeoVax Labs, Inc. | -25.96 Million USD | -190.136% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 77.035% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -131.507% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 431.598% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 23.74% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -0.783% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 53.149% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 87.751% |
| Evaxion Biotech A/S | -22.12 Million USD | -240.515% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 6.685% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 62.343% |
| Trevena, Inc. | -40.28 Million USD | -86.996% |
| Surrozen, Inc. | -43.04 Million USD | -75.036% |
| Tyra Biosciences, Inc. | -69.13 Million USD | -8.975% |
| Cingulate Inc. | -23.53 Million USD | -220.115% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -989.974% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -89.009% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -877.074% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 16.485% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | -22.93% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | -26.614% |
| Clearmind Medicine Inc. | -11.95 Million USD | -530.187% |
| Kronos Bio, Inc. | -112.67 Million USD | 33.135% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | -8.876% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -2970411.35% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 12.289% |
| Statera Biopharma, Inc. | -174.4 Million USD | 56.803% |
| ImmunityBio, Inc. | -583.19 Million USD | 87.082% |
| Korro Bio, Inc. | -81.17 Million USD | 7.186% |
| Kineta, Inc. | -14.09 Million USD | -434.357% |
| BioVie Inc. | -32.12 Million USD | -134.551% |
| Codexis, Inc. | -76.24 Million USD | 1.182% |
| Celularity Inc. | -196.29 Million USD | 61.62% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 64.882% |
| Celcuity Inc. | -63.77 Million USD | -18.125% |
| Virax Biolabs Group Limited | -6.73 Million USD | -1018.862% |
| Cibus, Inc. | -267.62 Million USD | 71.849% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -86.825% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -110.379% |
| IN8bio, Inc. | -30 Million USD | -151.071% |
| Kodiak Sciences Inc. | -260.49 Million USD | 71.078% |
| Annexon, Inc. | -134.23 Million USD | 43.876% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 35.698% |
| Assembly Biosciences, Inc. | -61.22 Million USD | -23.047% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -138.838% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 79.432% |
| Eyenovia, Inc. | -27.26 Million USD | -176.361% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 448.937% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -13982.056% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 1.394% |
| Arcellx, Inc. | -70.69 Million USD | -6.577% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -81.798% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 43.7% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -150.821% |
| Moolec Science SA | -51.78 Million USD | -45.473% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -43.856% |
| Geron Corporation | -184.12 Million USD | 59.083% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -79.49% |
| Royalty Pharma plc | 1.13 Billion USD | 106.639% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 44.586% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -747.286% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -254.649% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 56.114% |
| Humacyte, Inc. | -110.77 Million USD | 31.99% |
| Structure Therapeutics Inc. | -89.62 Million USD | 15.935% |
| 89bio, Inc. | -142.18 Million USD | 47.015% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | -9.25% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -626.019% |
| Genelux Corporation | -28.29 Million USD | -166.244% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -159.209% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 57.464% |
| Notable Labs, Ltd. | -11.26 Million USD | -568.848% |
| Liquidia Corporation | -78.5 Million USD | 4.029% |
| Mustang Bio, Inc. | -51.6 Million USD | -46.0% |
| Immunovant, Inc. | -259.33 Million USD | 70.949% |
| Quantum-Si incorporated | -95.96 Million USD | 21.489% |
| Arbutus Biopharma Corporation | -72.84 Million USD | -3.418% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -288.726% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 21.514% |
| Acasti Pharma Inc. | -12.85 Million USD | -486.159% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -235.468% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -372.0% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 58.694% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -1651.452% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -504.162% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -155.464% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -93.236% |
| PepGen Inc. | -78.62 Million USD | 4.181% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -153.079% |
| United Therapeutics Corporation | 984.8 Million USD | 107.65% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -238.45% |
| Solid Biosciences Inc. | -96.01 Million USD | 21.534% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1472.358% |
| Immuneering Corporation | -53.47 Million USD | -40.895% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -1381.002% |
| Silo Pharma, Inc. | -3.7 Million USD | -1935.813% |
| Belite Bio, Inc | -31.63 Million USD | -138.173% |
| XOMA Corporation | -40.83 Million USD | -84.514% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | -38.58% |
| Bionomics Limited | -15.49 Billion USD | 99.514% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 10.295% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -158.391% |
| uniQure N.V. | -308.47 Million USD | 75.577% |
| Cassava Sciences, Inc. | -97.21 Million USD | 22.504% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -930.386% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 38.962% |
| Forte Biosciences, Inc. | -31.47 Million USD | -139.354% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -818.578% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -159.182% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -13982.056% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -187.203% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -357.015% |
| Altimmune, Inc. | -88.44 Million USD | 14.82% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 50.299% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -158.391% |
| Compugen Ltd. | -18.75 Million USD | -301.722% |
| Peak Bio, Inc. | -1259.26 USD | -5982699.422% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -63.606% |
| Benitec Biopharma Inc. | -21.75 Million USD | -246.37% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 77.762% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 9.18% |
| Zura Bio Limited | -60.36 Million USD | -24.816% |
| PolyPid Ltd. | -23.86 Million USD | -215.688% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -378.89% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 9.18% |
| Instil Bio, Inc. | -156.08 Million USD | 51.733% |
| argenx SE | -295.05 Million USD | 74.466% |
| Immunome, Inc. | -106.8 Million USD | 29.462% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -77.293% |
| Verona Pharma plc | -54.36 Million USD | -38.57% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 24.598% |
| Shattuck Labs, Inc. | -87.29 Million USD | 13.699% |
| CervoMed Inc. | -2.17 Million USD | -3368.849% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 39.56% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -465.778% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -72.974% |
| Moolec Science SA | -51.78 Million USD | -45.473% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -435593.826% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 44.242% |
| AnaptysBio, Inc. | -163.61 Million USD | 53.955% |
| Design Therapeutics, Inc. | -66.86 Million USD | -12.678% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 7.462% |
| NeurAxis, Inc. | -14.62 Million USD | -415.079% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -98.878% |
| Lumos Pharma, Inc. | -34.03 Million USD | -121.364% |
| Achilles Therapeutics plc | -69.66 Million USD | -8.145% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 24.598% |
| 180 Life Sciences Corp. | -19.93 Million USD | -277.921% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 2603.963% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -2970411.35% |
| Nutriband Inc. | -5.48 Million USD | -1273.467% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 25.182% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -54.996% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 2.273% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -121.781% |
| MoonLake Immunotherapeutics | -36 Million USD | -109.233% |
| Palisade Bio, Inc. | -12.3 Million USD | -512.512% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -78.851% |
| Beam Therapeutics Inc. | -132.52 Million USD | 43.152% |
| Neurogene Inc. | -36.31 Million USD | -107.448% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 53.897% |
| AEON Biopharma, Inc. | -52.55 Million USD | -43.35% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 23.239% |
| Sesen Bio, Inc. | -19.88 Million USD | -278.893% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | -5.246% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -502.043% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 83.033% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 32.471% |
| Athira Pharma, Inc. | -117.67 Million USD | 35.975% |
| Vaccinex, Inc. | -20.25 Million USD | -272.026% |
| HCW Biologics Inc. | -24.99 Million USD | -201.425% |
| XOMA Corporation | -40.83 Million USD | -84.514% |
| Nektar Therapeutics | -276.05 Million USD | 72.709% |
| Arvinas, Inc. | -367.3 Million USD | 79.488% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -111803.453% |
| Merus N.V. | -154.93 Million USD | 51.375% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 22.672% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -140.048% |
| Rezolute, Inc. | -68.45 Million USD | -10.05% |
| Clene Inc. | -49.5 Million USD | -52.188% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -388.47% |
| BeyondSpring Inc. | -21.02 Million USD | -258.314% |
| Synlogic, Inc. | -57.28 Million USD | -31.523% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -533.048% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -595.908% |
| Peak Bio, Inc. | -1259.26 USD | -5982699.422% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -101.614% |
| Krystal Biotech, Inc. | 10.93 Million USD | 789.16% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 47.352% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 76.826% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -1531.08% |
| MannKind Corporation | -11.93 Million USD | -531.086% |
| Ikena Oncology, Inc. | -68.16 Million USD | -10.523% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -258.501% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 18.932% |
| Gossamer Bio, Inc. | -179.81 Million USD | 58.102% |
| CohBar, Inc. | -11.96 Million USD | -529.813% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -192.148% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -149.881% |
| Legend Biotech Corporation | -518.25 Million USD | 85.463% |
| Mural Oncology plc | -207.44 Million USD | 63.683% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 39.299% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -311.92% |
| Disc Medicine, Inc. | -76.42 Million USD | 1.426% |
| Champions Oncology, Inc. | -7.27 Million USD | -935.445% |
| REGENXBIO Inc. | -263.49 Million USD | 71.408% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -609.87% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -58.592% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -98.347% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 24.784% |
| Vaxart, Inc. | -82.46 Million USD | 8.641% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 22672.604% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -100.677% |
| Cellectis S.A. | -101.05 Million USD | 25.45% |
| Longeveron Inc. | -21.41 Million USD | -251.838% |
| Repare Therapeutics Inc. | -93.79 Million USD | 19.678% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 85.944% |
| Inozyme Pharma, Inc. | -71.16 Million USD | -5.859% |
| Revolution Medicines, Inc. | -436.36 Million USD | 82.735% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -1046.538% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -144.417% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | -8.663% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | -16.386% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -667.903% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 102.081% |
| Denali Therapeutics Inc. | -145.22 Million USD | 48.122% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -62549.891% |
| Veru Inc. | -93.15 Million USD | 19.123% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -178.734% |
| Cingulate Inc. | -23.53 Million USD | -220.115% |
| Passage Bio, Inc. | -102.06 Million USD | 26.183% |
| Context Therapeutics Inc. | -23.96 Million USD | -214.381% |
| Exicure, Inc. | -16.91 Million USD | -345.424% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 60.121% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -99.5% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -1057.757% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 59.205% |
| Nuvalent, Inc. | -126.21 Million USD | 40.311% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -616.446% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 13.283% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -146.657% |
| OmniAb, Inc. | -50.61 Million USD | -48.835% |
| Anew Medical, Inc. | 1.34 Million USD | 5696.731% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -369.548% |
| Lipocine Inc. | -16.35 Million USD | -360.73% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | -13.473% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | -18.318% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -78.555% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -57.064% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -279.905% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 86.087% |
| Ocugen, Inc. | -63.07 Million USD | -19.438% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 21.302% |
| Q32 Bio Inc. | -112.96 Million USD | 33.305% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -338.221% |
| Alumis Inc. Common Stock | -154.99 Million USD | 51.392% |
| Equillium, Inc. | -13.33 Million USD | -464.972% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | -24.804% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -843.172% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -299.65% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -27.516% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 34.217% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -309.942% |
| Dominari Holdings Inc. | -22.88 Million USD | -229.25% |
| Edesa Biotech, Inc. | -8.37 Million USD | -799.633% |
| vTv Therapeutics Inc. | -20.25 Million USD | -272.044% |
| Bio-Techne Corporation | 168.1 Million USD | 144.817% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 78.602% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 158.469% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 38.162% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -98.579% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 33.116% |
| Nkarta, Inc. | -117.5 Million USD | 35.882% |
| BioCardia, Inc. | -11.57 Million USD | -551.102% |
| Iterum Therapeutics plc | -38.37 Million USD | -96.344% |